$KALV
KalVista Pharmaceuticals, Inc.

2017 Q1 Form 10-Q Financial Statement

#000156459017004659 Filed on March 16, 2017

View on sec.gov

Income Statement

Concept 2017 Q1 2016 Q2 2016 Q1
Revenue $248.0K $314.0K $348.0K
YoY Change -28.74% 3040.0% 3380.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.030M $2.600M $1.540M
YoY Change 226.62% 122.22% 52.48%
% of Gross Profit
Research & Development $3.339M $947.0K $3.622M
YoY Change -7.81% -78.96% -7.18%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $34.00K
YoY Change -100.0% -100.0% 9.68%
% of Gross Profit
Operating Expenses $8.365M $5.400M $4.163M
YoY Change 100.94% -4.83% -15.18%
Operating Profit -$8.117M -$3.815M
YoY Change 112.77% -22.16%
Interest Expense -$190.0K -$390.0K $88.00K
YoY Change -315.91% 129.41% -89.47%
% of Operating Profit
Other Income/Expense, Net $473.0K $0.00 $1.863M
YoY Change -74.61% -100.0% -758.3%
Pretax Income -$7.640M -$7.350M -$6.610M
YoY Change 15.58% -18.42% 27.61%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$7.644M -$4.869M -$1.952M
YoY Change 291.6% -45.97% -62.35%
Net Earnings / Revenue -3082.26% -1550.64% -560.92%
Basic Earnings Per Share
Diluted Earnings Per Share -$997.4K -$3.910M -$3.516M
COMMON SHARES
Basic Shares Outstanding 26.33M
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q1 2016 Q2 2016 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $33.50M $36.80M $48.50M
YoY Change -30.93% -43.73% 1415.63%
Cash & Equivalents $33.50M $21.76M $24.17M
Short-Term Investments
Other Short-Term Assets $1.200M $1.100M $1.000M
YoY Change 20.0% -31.25% -9.09%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $38.00M $24.67M $49.50M
YoY Change -23.23% -63.18% 1049.03%
LONG-TERM ASSETS
Property, Plant & Equipment $100.0K $74.00K $200.0K
YoY Change -50.0% -81.5% -39.21%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $100.0K $100.0K
YoY Change -50.0% -44.13%
Total Long-Term Assets $100.0K $13.34M $175.0K
YoY Change -42.86% 2122.67% -94.86%
TOTAL ASSETS
Total Short-Term Assets $38.00M $24.67M $49.50M
Total Long-Term Assets $100.0K $13.34M $175.0K
Total Assets $38.10M $38.01M $49.68M
YoY Change -23.3% -43.78% 544.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $800.0K $187.0K $793.0K
YoY Change 0.88% -90.65% -68.84%
Accrued Expenses $2.400M $1.713M $1.082M
YoY Change 121.81% 0.76% -40.94%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $2.000M
YoY Change -100.0% 81.82%
Total Short-Term Liabilities $3.200M $1.929M $3.854M
YoY Change -16.97% -54.07% -64.98%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $2.700M
YoY Change -100.0% -100.0% -20.59%
Other Long-Term Liabilities $0.00 $0.00
YoY Change -100.0% -100.0%
Total Long-Term Liabilities $0.00 $0.00 $2.700M
YoY Change -100.0% -100.0% -55.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.200M $1.929M $3.854M
Total Long-Term Liabilities $0.00 $0.00 $2.700M
Total Liabilities $3.200M $1.971M $6.604M
YoY Change -51.54% -76.25% -61.44%
SHAREHOLDERS EQUITY
Retained Earnings -$51.65M -$86.58M -$79.23M
YoY Change -34.8% 49.6%
Common Stock $89.40M $122.6M $122.3M
YoY Change -26.9% 12229800.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.85M -$37.11M $43.07M
YoY Change
Total Liabilities & Shareholders Equity $38.05M $38.01M $49.68M
YoY Change -23.4% -43.78% 544.13%

Cashflow Statement

Concept 2017 Q1 2016 Q2 2016 Q1
OPERATING ACTIVITIES
Net Income -$7.644M -$4.869M -$1.952M
YoY Change 291.6% -45.97% -62.35%
Depreciation, Depletion And Amortization $0.00 $0.00 $34.00K
YoY Change -100.0% -100.0% 9.68%
Cash From Operating Activities -$7.120M -$7.260M -$5.080M
YoY Change 40.16% 12.73% 25.43%
INVESTING ACTIVITIES
Capital Expenditures $180.0K -$70.00K $184.0K
YoY Change -2.17% -12.5% 2.22%
Acquisitions
YoY Change
Other Investing Activities $33.96M $180.0K
YoY Change
Cash From Investing Activities $34.13M $120.0K -$180.0K
YoY Change -19061.11% -250.0% 0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 4.490M -4.500M 0.000
YoY Change -106.55% -100.0%
NET CHANGE
Cash From Operating Activities -7.120M -7.260M -5.080M
Cash From Investing Activities 34.13M 120.0K -180.0K
Cash From Financing Activities 4.490M -4.500M 0.000
Net Change In Cash 31.50M -11.64M -5.260M
YoY Change -698.86% -118.71% 630.56%
FREE CASH FLOW
Cash From Operating Activities -$7.120M -$7.260M -$5.080M
Capital Expenditures $180.0K -$70.00K $184.0K
Free Cash Flow -$7.300M -$7.190M -$5.264M
YoY Change 38.68% 13.05% 24.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
356000
CY2016Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
1883000
CY2016Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
546000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
2196000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1310000
CY2016Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1863000
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
473000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1304000
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
668000
CY2016Q2 us-gaap Assets Current
AssetsCurrent
24671000
CY2017Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7478000
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
74000
CY2017Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9713042
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
0
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3339000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5026000
CY2017Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
0
CY2017Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9713042
CY2016Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3622000
us-gaap Operating Expenses
OperatingExpenses
18643000
CY2017Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10784000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1511000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.03
CY2017Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
166000
CY2016Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
630921
CY2016Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.85
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-5.50
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-8117000
CY2017Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
661000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2852000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-16.05
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3013073
CY2016Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5574000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
576181
CY2016Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3815000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3531000
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-7644000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-17233000
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7657874
us-gaap Operating Income Loss
OperatingIncomeLoss
-9786000
CY2016Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
20000
us-gaap Investment Income Interest
InvestmentIncomeInterest
31000
us-gaap Investment Income Interest
InvestmentIncomeInterest
31000
CY2017Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-195000
CY2016Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1297000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-4529000
CY2016Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3622000
CY2017Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2016Q2 kalv Ordinary Shares Value
OrdinarySharesValue
3000
CY2017Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
89399000
CY2017Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51653000
CY2017Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-2907000
CY2017Q1 us-gaap Stockholders Equity
StockholdersEquity
34849000
CY2017Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38050000
CY2017Q1 kalv Ordinary Shares Par Value
OrdinarySharesParValue
0.0016
CY2016Q2 kalv Ordinary Shares Par Value
OrdinarySharesParValue
0.0016
CY2017Q1 kalv Ordinary Shares Issued
OrdinarySharesIssued
0
CY2016Q2 kalv Ordinary Shares Issued
OrdinarySharesIssued
2167367
CY2017Q1 kalv Ordinary Shares Outstanding
OrdinarySharesOutstanding
0
CY2016Q2 kalv Ordinary Shares Outstanding
OrdinarySharesOutstanding
2167367
CY2017Q1 us-gaap Revenue From Grants
RevenueFromGrants
248000
CY2016Q1 us-gaap Revenue From Grants
RevenueFromGrants
348000
us-gaap Revenue From Grants
RevenueFromGrants
1390000
us-gaap Revenue From Grants
RevenueFromGrants
1850000
us-gaap Operating Expenses
OperatingExpenses
11636000
us-gaap Operating Income Loss
OperatingIncomeLoss
-17253000
CY2015Q2 us-gaap Stockholders Equity
StockholdersEquity
-23555000
CY2016 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1000
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
118000
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-11436000
CY2016 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2240000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
29000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
228000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
16000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
1464000
us-gaap Foreign Currency Transaction Gain Loss Realized
ForeignCurrencyTransactionGainLossRealized
2230000
kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
1303000
kalv Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
1309000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
689000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
389000
kalv Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-36000
kalv Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
53000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1957000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-203000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1560000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-371000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-21081000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10768000
us-gaap Cash Acquired From Acquisition
CashAcquiredFromAcquisition
34139000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
34072000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9000
us-gaap Proceeds From Issuance Of Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
33002000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
33002000
us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
-1259000
us-gaap Effect Of Exchange Rate On Cash
EffectOfExchangeRateOnCash
-583000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11734000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
21642000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2832000
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2526000
CY2016Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
24168000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
58608000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The<font style="color:#000000;"> preparation of financial statements in conformity with U.S.&#160;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. </font></p></div>
CY2016Q4 us-gaap Business Acquisition Percentage Of Voting Interests Acquired
BusinessAcquisitionPercentageOfVotingInterestsAcquired
0.81
kalv Undistributed Loss Allocated To Convertible Preferred Share Holders
UndistributedLossAllocatedToConvertiblePreferredShareHolders
0
CY2017Q1 kalv Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-7855000
CY2016Q1 kalv Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-3059000
kalv Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-16573000
kalv Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-9245000
CY2017Q1 kalv Severance Legal And Other Professional Services Costs
SeveranceLegalAndOtherProfessionalServicesCosts
1200000
kalv Severance Legal And Other Professional Services Costs
SeveranceLegalAndOtherProfessionalServicesCosts
2900000
CY2017Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
252000
CY2016Q1 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
355000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
1408000
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
1872000
CY2017Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-9564000
CY2016Q1 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-7035000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-19963000
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-21862000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
0
CY2017Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
672000
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
967000
CY2017Q1 kalv Accrued Research And Clinical Trial Expenses
AccruedResearchAndClinicalTrialExpenses
959000
CY2016Q2 kalv Accrued Research And Clinical Trial Expenses
AccruedResearchAndClinicalTrialExpenses
1059000
CY2017Q1 kalv Accrued Professional Fees Excluding Legal Fees Current
AccruedProfessionalFeesExcludingLegalFeesCurrent
349000
CY2016Q2 kalv Accrued Professional Fees Excluding Legal Fees Current
AccruedProfessionalFeesExcludingLegalFeesCurrent
59000
CY2017Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
466000
kalv Number Of Grant Income Agreements
NumberOfGrantIncomeAgreements
2
CY2017Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00
CY2017Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
333000
CY2017Q1 us-gaap Significant Change In Unrecognized Tax Benefits Is Reasonably Possible Amount Of Unrecorded Benefit
SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit
0
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0

Files In Submission

Name View Source Status
0001564590-17-004659-index-headers.html Edgar Link pending
0001564590-17-004659-index.html Edgar Link pending
0001564590-17-004659.txt Edgar Link pending
0001564590-17-004659-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kalv-10q_20170131.htm Edgar Link pending
kalv-20170131.xml Edgar Link completed
kalv-20170131.xsd Edgar Link pending
kalv-20170131_cal.xml Edgar Link unprocessable
kalv-20170131_def.xml Edgar Link unprocessable
kalv-20170131_lab.xml Edgar Link unprocessable
kalv-20170131_pre.xml Edgar Link unprocessable
kalv-ex101_523.htm Edgar Link pending
kalv-ex102_524.htm Edgar Link pending
kalv-ex311_8.htm Edgar Link pending
kalv-ex312_7.htm Edgar Link pending
kalv-ex321_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending